Respiratory & Pulmonary Trials - High Point Clinical Trials Center

Respiratory & Pulmonary Trials


  • Patient-centric facility with 24/7 medical oversight
  • Medical Staff experienced conducting Pulmonary Function Tests (Spirometry/FVC)


  • In-Patient and Out-Patient Studies assessing:
    • BA/BE and PK/PD
    • Combination of SAD/MAD, FE, and POC Adaptive Designs generating cost and time savings
    • Ability to support multiple ROAs (oral, sub-lingual, IV, nasal, subcutaneous, intramuscular, parenteral, inhalation, infusion)


✓ Dedicated in-house marketing team
and relationships with referring Specialists


✓ CTMS-driven database with ability
to target and retrieve Patient profiles based on I/E criteria


✓ Active volunteering at community events, health fairs and the Community Clinic of High Point offering Spirometry and FVC testing


COPD Asthma Emphysema


North Carolina offers favorable demographics for the recruitment of Patients suffering from Chronic Obstructive Pulmonary Disease (COPD), Asthma and other chronic pulmonary diseases. High Point Clinical Trials Center can leverage industry-leading recruitment capabilities, targeting specific Patients with research study opportunities that may help them improve or better manage their condition.


  • According to a recent article, more than 7% of North Carolina’s population (approx. 500,000 people) has COPD or Asthma.
  • More than 900,000 (12.6%) adults in North Carolina have been diagnosed with asthma, and approximately 535,000 still have it.
  • In 2015, the prevalence of cigarette smoking among adults in North Carolina was 19.0%, chronic tobacco smoking is a major cause of chronic obstructive pulmonary disease (COPD)
  • High Point CTC maintains a database of 6000+ cigarette smokers
“Emerging claims with regards to electronic cigarette’s (e-cigarette) usefulness to defer COPD (chronic obstructive pulmonary disease) and other smoking related diseases has launched a wave of clinical research. The basis of this increase in e-cigarette research is the hypothesis that the diminished combustion of product (i.e., smoke) is considered one of the key factors on which e-cigarette producers claim pulmonary improvement with their use.”

Read more…